CoChat

Comparison of glucose‐lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta‐analysis of randomized controlled trials

Open access
Zaccardi, Francesco, Dhalwani, Nafeesa N., Dales, Jolyon, Mani, Hamid, Khunti, Kamlesh, Davies, Melanie J., Webb, David R. · 2018 · Diabetes, Obesity and Metabolism
Cited by 30

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Aims: To assess the evidence supporting the choice of third‐line agents in adults with inadequately controlled type 2 diabetes. Materials and methods: We searched randomized controlled trials (RCTs) published between January 2000 and July 2017 that reported data on cardiometabolic outcomes and hypoglycaemia for glucose‐lowering agents added to metformin‐based dual treatments. Data were stratified by background therapy and RCT duration, and synthesized, when possible, with network meta‐analyses. Results: A total of 43 RCTs (16 590 participants) were included, with metformin combined with: sulphonylureas (SUs) in 20 RCTs; thiazolidinediones (TZDs) in 10; basal or rapid‐acting insulin in 6; dipeptidyl peptidase‐4 (DPP‐4) inhibitors in 3; glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in 2; and sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors in 2. When added to metformin and SUs, after 24 to 36 weeks, rapid‐acting insulin resulted in the largest reduction in glycated haemoglobin (HbA1c; 1.6% vs placebo), followed by GLP‐1RAs (1.0%), basal insulin (0.8%) and SGLT‐2 inhibitors (0.7%), with no difference between GLP‐1RAs and SGLT‐2 inhibitors; body weight increased with insulin treatment (~3 kg vs placebo), while the greatest reduction was observed for SGLT‐2 inhibitors compared with all other therapies. Limited data for hypoglycaemia indicated a similar risk for SGLT‐2 inhibitors and GLP‐1RAs. Results for third‐line agents added to metformin and TZDs were comparable, showing similar HbA1c reduction and risk of hypoglycaemia between SGLT‐2 inhibitors and GLP‐1RAs, and a slightly greater reduction in body weight with SGLT‐2 inhibitors vs GLP‐1RAs. Data for 52 to 54 weeks were more limited: added to metformin and a SU, TZDs, GLP‐1RAs or SGLT‐2 inhibitors reduced HbA1c to a similar extent but had different effects on body weight (7 kg and 5 kg more with TZDs vs SGLT‐2 inhibitors and GLP‐1RAs, respectively; 2 kg less when comparing SGLT‐2 inhibitors with GLP‐1RAs). Formal analyses could not be performed for any other dual therapy failure combinations because of the small number of available RCTs. Conclusions: Moderate‐quality evidence supports the choice of a third‐line agent only in patients on metformin combined with a SU or a TZD, with SGLT‐2 inhibitors performing generally better than other drugs. In suggesting third‐line agents, future guidelines should recognize the widely differing evidence on the various dual therapy failures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13185

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

Metadata

Authors
Zaccardi, F., Dhalwani, N. N., Dales, J., Mani, H., Khunti, K., Davies, M. J., & Webb, D. R.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-01-08
Volume
20
Issue
4
Pages
985-997
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2774592377
Cited by
30
References
11
FWCI
0.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.